Cancer Management and Research (Oct 2022)

Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors

  • Li D,
  • Darden C,
  • Osman N,
  • Sayeed S,
  • Jackson L,
  • Garbinsky D,
  • Chauhan A

Journal volume & issue
Vol. Volume 14
pp. 3009 – 3020

Abstract

Read online

Daneng Li,1 Christina Darden,2 Noran Osman,3 Salma Sayeed,3 Laurin Jackson,2 Diana Garbinsky,2 Aman Chauhan4 1City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA; 2RTI Health Solutions, Research Triangle Park, NC, USA; 3TerSera Therapeutics, Deerfield, IL, USA; 4Markey Cancer Center, University of Kentucky, Lexington, KY, USACorrespondence: Daneng Li, Department of Medical Oncology & Therapeutics Research, City of Hope, 1500 E. Duarte Road, Duarte, CA, 91010, USA, Tel +626-471-9200, Fax +626-301-8233, Email [email protected]: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor approved for the treatment of carcinoid syndrome diarrhea (CSD) in combination with somatostatin analogs (SSAs).Methods: This prospective, observational, single-arm study evaluated long-term patient-reported outcomes for adults initiating TE in US clinical practice from 2017 through January 2022. The primary objective was satisfaction with overall CS symptom control 6 months after initiating TE. Secondary objectives evaluated satisfaction with control of CSD, flushing, and CS symptoms, as well as work productivity/activity impairment, SSA use, and weight. All analyses were descriptive in nature.Results: A total of 223 patients completed the baseline survey; 56% also completed the 6-month follow-up survey. Mean age was 61 years and 61% were women. After 6 months of TE treatment, the majority of patients (76%, n=95/125) reported being satisfied with control of their CS symptoms which was markedly improved from baseline (41%, n=91). Similarly, the majority of patients (78%, n=97/125) were satisfied with control of their CSD after 6 months of TE, markedly improved from baseline (36%).Conclusion: This longitudinal observational study showed improvements in real-world clinical and humanistic outcomes for patients with CS and at least 6 months of TE treatment.Keywords: neuroendocrine tumors, gastrointestinal neoplasms, medical management, carcinoid syndrome, telotristat ethyl, work productivity, healthcare resource use

Keywords